信达生物奔跑200亿 俞德超进阶路上的是与非

投资者网
21 Feb

大水大鱼的选择。作者丨蔡俊思维财经&投资者网 出品丨ID:touzizhebao信达生物(01801.HK,下称“公司”)朝着200亿目标,又迈出一步。近期,公司披露2024年产品收入。此前,公司喊出200亿产品收入目标,一时备受市场关注。创新药从风口步入寒冬,公司见证行业的起起伏伏,其发展与壮大在选择与努力间寻找一个平衡。大水大鱼的创新药上世纪90年代,远在美国的俞德超遇到一个改变人生的事件:其...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10